Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Teewinot Life Sciences Corporation is Producing Cannabinoids without Touching the Plant

  • Producing cannabinoids through biosynthesis
  • CANNSYNTHESIS® platform has capacity to scale up
  • Revenues from out-licensing technology

For the half a billion or so who suffer from one type or another of diabetes, biosynthesis offers a lifeline. For it is through biosynthesis that much of the world’s insulin is produced. Insulin regulates the metamorphosis of fats and protein and, importantly, allows the cells in the muscles, fat and liver to absorb glucose from the blood. When the body does not produce enough insulin nor use the insulin it produces efficiently, blood sugar levels may rise dangerously. However, biosynthesis, a mid-twentieth century technology, is not employed solely in producing insulin but finds application in many other fields. For example, Teewinot Life Sciences Corporation uses biosynthesis to produce cannabinoids, a method of manufacture that is much less costly than growing cannabis plants and extracting the cannabinoids. With biosynthesis, Teewinot Life Sciences is able to produce cannabinoids without touching the cannabis plant.

Despite changing attitudes, cannabis remains a prohibited or controlled substance in many jurisdictions worldwide. In the U.S., for example, it is regulated pursuant to the Controlled Substances Act of 1970, under which authorities have classified marijuana as a Schedule I drug, alongside heroin and LSD. By so doing, all cannabinoids risk being tainted with illegality if they are extracted from the marijuana plant. However, most cannabinoids produced biosynthetically may escape the prohibitions of the CSA, since only THC is specifically mentioned in Schedule I.

Teewinot manufactures cannabinoids that have the same chemical structure as naturally-occurring phytocannabinoids by means of its patent-protected methods. These proprietary methods of manufacturing cannabinoids are less expensive than growing cannabis plants and extracting the cannabinoids. Moreover, the technology can be used to cost-effectively manufacture cannabinoid pro-drugs and cannabinoid analogs that do not naturally occur in the cannabis plant. A pro-drug is a substance that is metabolized by the body into a pharmacologically-active agent. Perhaps the best known pro-drug is paracetamol (acetaminophen), which is now thought to exert its analgesic (and probably anti-pyretic) effects by metamorphosizing into an anandamide, an endocannabinoid. In very general terms, this means that in the human body, paracetamol degrades to a cannabimimetic, or a substance that mimics a cannabinoid.

Developed by its labs in Vancouver, British Columbia, and Steinbach, Manitoba, this groundbreaking biosynthesis technology has long outgrown its micro environment. Teewinot Life Sciences has developed CannSynthesis™ to be employed for the large-scale manufacture of pharmaceutically pure cannabinoids. The technology has been licensed for the commercial production of the first analytical standard of CBCA (cannabichromenic acid) and for the manufacture of a patent-protected pro-drug of a cannabinoid. Teewinot’s cannabinoid pro-drugs are designed to be more bioavailable and stable in the human body, thereby increasing their efficacy.

Apart from THC and CBD, many of the 111 or so cannabinoids found in the cannabis plant are produced in minute quantities. Production by extraction is thus prohibitively costly, meaning that most cannabinoids have not been available for research and therapeutic applications. The CANNSYNTHESIS® platform has changed that paradigm, however, since it allows for the efficient production of cannabinoids in kilogram quantities. Teewinot’s CANNSYNTHESIS® has taken the production of cannabinoids from the lab to clinical settings, since the technology can deliver consistent and controlled dosages. Buoyed by its successes, the company continues to work with leading universities and pharmaceutical companies to provide novel patient therapies.

For more information, visit the company’s website at www.TLSCorp.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Opportunity Amid Cannabis Banking Hurdles

CannabisNewsWire Editorial Coverage: Investors seeking opportunities in the cannabis market may want to turn their attention toward companies offering solutions for a situation that could otherwise slow the industry’s growth. A number of emerging firms are providing or pursuing payment options that can help cannabis companies sidestep the roadblock created by the lack of access to traditional banking services. Among the companies honing financing, payment processing and other business development services for the cannabis industry are Global Payout, Inc (OTC: GOHE) (GOHE Profile), MassRoots Retail (OTC: MSRT), iAnthus Capital Holdings, Inc. (CSE: IAN) (OTC: ITHUF), and Glance Technologies, Inc. (OTC: GLNNF) (GET: CNX). Meanwhile, recent action at Canopy Growth Corp. (CC: WEED) demonstrates that a change in bank industry policy could be on the horizon.

In Arizona, the state Department of Health Services reported that its dispensaries sold over 43 tons of medical marijuana through year-end 2017, an increase of 48 percent from 2016. Capitol Media Services estimates the quantity of medical marijuana sold in Arizona in 2017 represented approximately $275 million in retail sales for the year. Sales in the United States as a whole represent a multibillion dollar market that is only expected to grow as the legalization process continues to spread. In Canada alone, taking into account the planned July 2018 legalization of recreational cannabis, sales of the product are expected to reach C$6 billion by 2021.

Despite the massive sales figures, cannabis companies largely conduct business in cash. With marijuana classified as a Schedule 1 drug at the federal level in the United States, the cannabis industry is essentially unbankable there, creating an opportunity for companies that can help industry participants process the payments generated by cannabis sales.

The Struggle to Organize Necessary Elements of Infrastructure

For the time being, cannabis businesses continue to struggle with financing issues related to customer receipts and budget expenditures, especially in the United States. While U.S. banks have overwhelmingly refrained from doing business with cannabis companies due to the federal prohibition on sales of the product, in Canada some banks have begun to offer business accounts to cannabis companies. Even when Canada does begin legalization in mid-2018, however, there’s no guarantee its banks will be quick to finance cannabis companies. The year is expected to be a landmark period for cannabis-related businesses, yet there’s still a fair amount of uncertainty about how they will fare. Global Payout, Inc. (OTC: GOHE) is one company positioned to help alleviate that uncertainty through a number of payment processing services.

Payment Solutions for the “Unbankable”

Global Payout’s fintech payment solutions can be fully customized for virtually any domestic and international organization distributing money worldwide. Through its MoneyTrac Technology (“MTRAC”) subsidiary, Global Payout is focused on helping reduce the extensive security, accounting and overhead costs dispensaries face from having to deal exclusively in cash. The reliance on cash transactions by cannabis businesses leaves these companies vulnerable to theft and facing all the inconvenience associated with running a cash-only business. And the problem is only expected to grow more acute as the rapidly growing multibillion-dollar industry continues to expand, with cannabis now recreationally available in eight states.

Addressing this opportunity in the company’s letter to shareholders, Global Payout CEO James Hancock stated: “Recognizing the gap between adequate financial technology solutions and the rapidly expanding, multi-billion-dollar cannabis industry, a collective decision was made in March to spinout our majority owned subsidiary, MoneyTrac Technology to begin serving the underserved businesses of the cannabis industry. … These partnerships, combined with several other important developments throughout the year, have effectively positioned MoneyTrac to generate revenue and become a recognized leader of a variety of service and solution offerings within the cannabis industry.”

MTRAC plans to launch its regulatory compliant token offering in the first quarter of 2018 as part of an effective, decentralized system for processing payments (http://cnw.fm/eoPQ3). The M-Token from MTRAC will allow vulnerable businesses to migrate from a cash-only business model by offering the basic yet essential services denied to them by the traditional banking industry. In the process, the businesses can improve their security and boost their operational efficiency.

Vanessa Luna, CEO of MTRAC, stated, “MoneyTrac’s primary objective has been, and will continue to be, to serve the legitimate and profitable businesses of the cannabis industry by effectively addressing the financial technology and banking challenges they are faced with. … Our regulatory compliant Token Offering will revolutionize how these businesses operate and help MTRAC further its objectives for identifying various partnerships and cultivating the relationships necessary to pave the way for alternative banking solutions.”

Cannabis Compliance

To help it develop a strong foundation for the delivery of banking solutions to the legal cannabis industry, MTRAC recently signed a joint-venture agreement with Integrated Compliance Solutions, LLC (“ICS”), a leading provider of financial regulatory compliance services and solutions to the retail cannabis industry. The partnership bolsters MTRAC’s ability to provide compliant banking solutions with its strategic partners.

In the press release announcing the agreement, Luna emphasized the importance in maintaining compliance in the heavily regulated retail cannabis industry.

“The ICS team carries several years of valuable experience with them in the field of regulatory compliance solutions and financial technology services for banking, and their integration into the banking solutions (that) we are dedicated to delivering to the cannabis industry is not only significant, but essential to our commitment of providing retail cannabis businesses with the most compliant and regulated banking solution available,” she stated (http://cnw.fm/xiq7H).

Exploring Expanded Marketing Opportunities

Global Payout also recently signed a Sales Partnership Agreement with Eyeconic.tv in a move to explore the potential of creating new revenue streams (http://cnw.fm/vnXs7) while boosting the impact of both parties.

The companies plan to leverage the network of dispensaries and industry-specific brands and products established through MTRAC’s PotSaver publication in conjunction with Eyeconic.tv’s digital media platform. Eyeconic.tv is an innovative producer and distributor of interactive digital mediums focused mainly on digital menus, advertising and kiosks to customers on their business premises. PotSaver is a revenue-producing community periodical and online advertising platform that provides listings for discounted cannabis-related products to local dispensaries and shops.

“Establishing this sales partnership with Eyeconic.tv is an incredibly effective way to deliver more value to the solutions and services we are providing to cannabis-related businesses. The Eyeconic.tv team are true pioneers in the digital marketing and advertisement space and have established themselves as the premier provider of these services throughout the cannabis industry. I am pleased they recognize the value we can bring to their brand through the network of dispensaries we have created through our PotSaver publication, as well as through the invaluable expertise our team offers in developing and implementing successful sales and marketing strategies. I am extremely confident that this will be a partnership that is mutually beneficial to the objectives of each of our companies,” Luna said.

Additional Cannabis Payment Solution-Related Opportunities

In a sign that Canadian banks are beginning to change their position about financing cannabis firms, Canopy Growth Corp (CC: WEED), a diversified Canadian cannabis company that offers curated cannabis in dried, oil and capsule form, has recently announced a $175 million bought stock offering led by two major Canadian investment banks — Bank of Montreal, through its BMO Capital Markets division, and GMP Securities. Canopy Growth operates on four continents where it sells cannabis products, conducts R&D, and provides cannabis-related education for healthcare practitioners.

While Canadian banks may be beginning to change their stance on financing cannabis firms, it should be noted there are no signs of such a thaw to the south where banks continue to avoid doing business with cannabis firms because of federal regulations. Canopy Growth’s extensive operations outside of Canada mean that the firm can still benefit from payment solutions that enable it to reduce the amount of cash transactions it conducts.

MassRoots (OTC: MSRT) offers one of the most popular technology platforms for the regulated cannabis industry. The company’s mobile apps, with more than a million users, enable consumers to draw on community-sourced reviews to make educated cannabis purchasing decisions. The company offers a compliance and point-of-sale system called MassRoots Retail, which helps cannabis businesses conduct retail operations more efficiently and manage compliance reporting as required by state regulators. MassRoots has recently formed a blockchain subsidiary focused on developing solutions for the cannabis industry based on the blockchain. The company believes that making use of the transparent digital ledger that constitutes the blockchain can help the cannabis industry operate with greater efficiency, accountability and transparency.

iAnthus Capital Holdings (CSE: IAN) (OTC: ITHUF) offers investors exposure to licensed cannabis cultivators, processors and dispensaries located across the United States. The company offers capital as well as hands-on operational and management expertise. With seven investments in six states covering an addressable market of approximately 50 million people, the company’s dispensaries stand to benefit from access to innovative payment processing and financial solutions that enable them to more efficiently handle transactions.

Glance Technologies, Inc. (OTC: GLNNF) (GET: CNX) owns Glance Pay, a mobile payment system transforming the way smartphone users interact with merchants and buy products. The company’s partially owned subsidiary, Cannapay Financial, is the vehicle for Glance Technologies’ entry into the cannabis industry through licensing agreements that leverage the Glance Pay App and the Glance Merchant App’s data analytics. Cannapay Financial has two apps in development — Cannapay, a mobile-to-mobile payment system for the marijuana industry, and SuperDope Delivery, a mobile ordering and delivery app for cannabis consumers.

The tremendous growth being experienced by the cannabis industry, coupled with the difficulty cannabis businesses are experiencing in accessing banking services, especially in the United States, have created significant opportunities for firms that can offer these businesses effective methods of processing transactions. Each of the companies listed above is positioned to benefit from this evolving trend, making them worthy of further investigation by investors looking to capitalize on the expansion of the cannabis industry and the corresponding development of payment solutions to facilitate that expansion.

For more information on Global Payout, visit Global Payout, Inc. (GOHE)

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text “Cannabis” to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by CNW are solely those of CNW. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW for any investment decisions by their readers or subscribers. CNW is a news dissemination and financial marketing solutions provider and is NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW undertakes no obligation to update such statements.

Earth Science Tech, Inc. (ETST) Eyes Uplisting to OTCQB, Retains Counsel for Planned Regulation A+ Tier 2 Financing

  • Goal is to raise $4 million to help company finance its planned projects
  • Expansion into Canada eyed, attorney retained to help seek Canadian licenses to import ETST’s CBD-rich hemp oil into country
  • ETST would also use funding for MSN-2, its home kit for the detection of sexually transmitted diseases

Earth Science Tech, Inc. (OTC: ETST) is working toward an uplisting to the OTCQB Venture Market in early 2018. It has also retained counsel for a planned Regulation A+ Tier 2 round of financing, which the company hopes will raise an aggregate of $4 million (http://cnw.fm/W8I2d). The funds would be used to finance its planned projects in the new year and for general working capital (http://cnw.fm/Pi0hl), with share cancellation by company founders counteracting dilution.

ETST is also eyeing expansion into Canada in 2018, and it has appointed an attorney who will serve as consultant for ETST’s activities in that country, Avi Levi, Esq. (http://cnw.fm/aW8ww). He will help the company apply for licenses to import its CBD-rich hemp oil into Canada. It will then be exported to various countries as raw hemp oil or in individual ready-to-consume bottles, the company said.

Dr. Michel Aube, CEO and chief scientific officer of the company, said, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas and CBD based generic pharmaceutical drugs.”

The MSN-2 device is prepared for third-party evaluation ahead of manufacture and commercialization. The MSN-2 device is a home kit designed for the detection of sexually transmitted diseases.

ETST is a biotechnology company operating in the fields of hemp cannabinoid pharmaceutical, nutraceutical, and medical device R&D. Its hemp CBD is made using the liquid extraction process. As a result, its CBD oil is 100 percent natural and organic, as noted by the company.

ETST has three wholly owned subsidiaries. First, Earth Science Pharma, Inc. specializes in the development of medical devices for the treatment of sexually transmitted diseases. Second, Cannabis Therapeutics, Inc. works to explore the medicinal powers of CBD. Cannabis Therapeutics holds a provisional application patent for a CBD product which develops treatments for ovarian and breast cancers. Third, KannaBidioid, Inc. focuses on the recreational cannabis space.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

EVIO, Inc. (EVIO) is Exceeding Expectations

  • Investor interest nearly doubles size of placement
  • Company’s 2017 revenues soared 438 percent year-over-year
  • On pace to double number of testing facilities this year

The regulatory uncertainties surrounding cannabis will have little impact on the long-term growth of the industry. There’s overwhelming scientific evidence validating the medical efficacy of certain cannabinoids and, like all medications, cannabinoids require quality control assurances for potency and purity.  Also, much like prohibition, it’s realistic to expect parochial federal regulators to ultimately succumb to the will of the majority and relax any uncertainties around recreational cannabis use. Again, the end product must be tested and screened for potency and any potentially harmful byproducts.

EVIO, Inc. (OTCQB: EVIO) is the established national leader in such testing and verification, providing accredited cannabis testing, as well as high-quality analytical and consulting services for agricultural and biomedical industries in the United States. Operating coast-to-coast, the company’s EVIO Labs division provides state-mandated ancillary services to ensure both safety and quality of the nation’s cannabis supply. The company provides state-of the-art analytical testing and advisory services, and it performs extensive product research in its accredited laboratory testing facilities.

In a recent vote of confidence for EVIO, as well as in the long-term viability and opportunities in the cannabis industry, EVIO just closed a $5,973,000 private placement. The initial target of $3 million was nearly doubled due to investor interest in EVIO’s uniquely scalable business model and scientific expertise in the cannabis testing space (http://cnw.fm/GaCw2).

Market savants fully understand that fresh capital seldom flows to dead-end deals, and doubling the raise is a significant signal of potential success. The best-efforts offering was completed on January 30 through lead agent and bookrunner Dominick Capital Corporation of Toronto, Canada.

As further evidence of EVIO’s growth curve, the company reported a 438 percent revenue increase on a year-over-year basis in its fiscal year ended September 30, 2017 (http://cnw.fm/ZtN6O). The vast majority of this growth came from increased testing revenue, which was up 782 percent, while consulting services increased by 27 percent.

EVIO has grown from one laboratory in Oregon to nine fully operational laboratories in California, Colorado, Florida, Massachusetts and Oregon, and it intends to open 18 laboratory facilities at other locations around the United States by the end of 2018.

For more information, visit the company’s website at www.EVIOLabs.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Recent Report on PotNetwork Holding Inc. (POTN) Share Price Target Highlights Encouraging Data

  • Heightened share price target for PotNetwork Holding Inc. set at $1.25
  • Previous market estimates, exceeded by over 70 percent, show positive month-to-month sales for PotNetwork Holdings Inc.
  • SeeThruEquity report highlights the greatly lowered legal and physiological risk from hemp-derived CBD

A recent comprehensive report by SeeThruEquity highlighting PotNetwork Holding Inc. (OTC: POTN) and its subsidiary, Diamond CBD, projected a heightened share price target set at $1.25. The increase was attributed to the company’s strong monthly sales data and 3Q17 filings (http://cnw.fm/A2krk). Per the report, these indicated “continued profitability as the company invests in growth.”

In a prior news release, Dr. Richard Goulding, CEO of PotNetwork Holding Inc., stated, “It is very rewarding to experience this type of growth and success, and all the more pleasing to see an acknowledgement of our collective efforts in the marketplace.”  This statement followed news that the company’s previously announced estimates of $8.3 million were exceeded by over 70 percent, reaching $14.5 million due to rapid month-to-month growth in sales (http://cnw.fm/Rt1p8).

SeeThruEquity’s report highlighted that hemp derived from CBD can provide a legal alternative to marijuana-based CBD, which is banned by federal law. This allows consumers to make use of CBD products without the risk of experiencing a ‘high’ or infringing on government law. The projected market for hemp-derived CBD is expected to grow at a CAGR of roughly 53 percent through 2020, positioning it among the fastest-growing segments within the multi-billion dollar legal cannabis and hemp market.

Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the most researched derivatives of cannabis, a psychoactive drug also known as marijuana (http://cnw.fm/u83jV).  The traditional ‘high’ associated with this drug is largely thanks to the presence of THC, and, while CBD is a structural isomer of THC (meaning that it has the same chemical composition), the atomic structure is arranged differently, offering many of the same health benefits without the psychoactive effects of THC. Based on numerous studies, CBD has demonstrated the capacity to produce a number of effects on the endocannabinoid system (ECS), including boosting immune system function, reducing sensations of pain, playing a role in inflammatory response and altering appetite, mood, memory and energy levels.

With the advancement of technology and ongoing research of the medicinal qualities of CBD, it is possible that these products could, potentially, serve as substitutes for harmful medications that are currently on the market.  The natural healing properties are being assessed on a global level, and several journals have already noted the economic impact of CBD in general. Matt Karnes of Greenwave Advisors, in an interview with Forbes, stated, “In terms of the CBD market size, I estimate an almost $3 billion market by 2021. Right now, there are 15 states that allow CBD only — this is in addition to the 28 states plus DC that have legalized medical marijuana.”

Numerous studies on the positive effects of cannabinoids and THC have paved the way for legalization of marijuana for medicinal purposes in Canada and the U.S.  A focus report by Mackie Research Capital Corp. (http://cnw.fm/Dgh2g) notes that (based on internal models) the Canadian marijuana market is expected to increase in size quickly, with the forecast peak in market size to exceed C$2.5 billion by 2020. With the United States presenting various states in which medicinal marijuana is legal, the market size for these states (most notably Colorado, Arizona, Oregon and Michigan) is projected to record a significant increase in growth from 2015 to 2020. For the above-mentioned states, the Colorado market is expected to reach more than $1.5 billion, Arizona is expected to exceed $453 million, Oregon could increase to $330 million and Michigan is expected to rise to $556 million, all by 2020.

PotNetwork Holding Inc. is a publicly traded company that acts as a holding company for a number of subsidiaries, namely First Capital Venture Co., PotNetwork.com, and Diamond CBD, Inc.  The latter focuses on research, development and multinational marketing of hemp extracts containing a wide variety of cannabinoids and natural hemp derivatives.  Diamond CBD’s team of hemp industry pioneers, chemists, doctors, scientists and natural product experts aims to produce high-grade CBD oil, providing a variety of CBD oils, tinctures, edibles and vape liquids.

In a previous news release (http://cnw.fm/6q5VV), Goulding added, “[W]e are proud, and think our shareholders should be too, that on December 13, 2017 PotNetwork Holding was named by Huffington Post, a prominent major national news source, as “One of Five Notable CBD Revolution Industry Leaders’, an accolade that pays tribute to the company’s achievements and future prospects.”

Goulding further noted, “2017 has been a phenomenally successful year for us! Our unprecedented sales growth pays tribute to the hard work of our staff and our resellers, and the exceptional quality of our CBD product line which expanded greatly over 2017.” He also emphasized that the company is poised for growth during 2018 and it embarks on new and unique marketing initiatives and embraces new opportunities.

Without question, the recent report by SeeThruEquity highlighting PotNetwork Holding Inc. and Diamond CBD projects not only an increased share price target, but also a positive expansion of the company within this multi-billion dollar arena.  With an ever-increasing demand for safer products of this nature that abide by all governing regulations, PotNetwork Holding Inc., also with its subsidiaries, has its foot in the door of tomorrow’s market.

For more information, visit the company’s website at www.PotNetworkHolding.com

Pursuant to the applicable federal law, the sale or distribution of CBD with less than 0.03% of tetrahydrocannabinol by retailers may be permissible in all states.  However, the local, state and federal laws regarding these issues tend to remain in flux and should be accordingly reviewed by local counsel and, as such, legal advice is not intended, but specifically disclaimed.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Teewinot Life Sciences’ Patented Biosynthetic Tech Cuts Costs and Produces Clinical-Grade Cannabinoids

  • Company’s IP portfolio, including proprietary technology and biosynthetic methods, features seven U.S. patents and patent filings in numerous other key countries around the world
  • Eliminating the high costs of cultivating plants, Teewinot Life Sciences Corporation delivers pure, consistent pharmaceutical-grade cannabinoids
  • Company’s goal is to cut costs and approach cannabinoid production like a pharmaceutical company, not as a cannabis firm

Teewinot Life Sciences Corporation has an advantage in consistently producing pure, clinical-grade cannabinoids with its patented biosynthetic technology. The results eliminate the watering and electrical costs of traditional plant cultivation, as well as the variances in quality. Instead, its method offers low-cost cannabinoids in a pure, consistent clinical grade.

Teewinot Life Sciences is a Tampa, Florida-based global biopharmaceutical company focused on cannabinoid clinical development utilizing patented and proprietary synthetic biology and biocatalysis technology. Its strategy involves the production and use of cannabinoid molecules. The goal of the company is to produce, at lower cost, consistent and pure cannabinoids that it believes can be used to develop superior human therapies.

The company and its wholly-owned subsidiaries have patented technologies that produce individual cannabinoids at commercial scale for a wide variety of markets. It approaches the process as a straight medical company, not as a marijuana firm. Its process involves the pharmaceutical manufacture of cannabinoids through biocatalysis and synthetic biology.

Cannabinoid biosynthetic enzymes are produced in microorganisms transformed with cannabinoid biosynthetic genes. Those enzymes are then used to manufacture pharmaceutically-pure cannabinoids.

The goal is to improve human therapies. The company has now secured seven U.S. patents and has a portfolio of patent applications in a number of countries. Teewinot Life Sciences has subsidiaries in Ireland and Canada.

For more information, visit the company’s website at www.TLSCorp.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

ChineseInvestors.com, Inc. (CIIX) Offering Innovative Access to Cryptocurrency

  • Despite China’s ban on cryptocurrency, CIIX is positioned to lead the way in cryptocurrency education and awareness for the Chinese-speaking community
  • Demand for bitcoin continues to rise despite China’s ban on cryptocurrency
  • Company is committed to the education and growth of cryptocurrency and providing innovative ways of making bitcoin more accessible

ChineseInvestors.com, Inc. (OTCQB: CIIX) is continuing its commitment to cryptocurrency education and awareness for the Chinese-speaking community. Its educational services seek to answer the average person’s curiosity while simultaneously providing skilled investors with up-to-date news on digital currency. Using the Chinese language character sets, CIIX provides analysis and education that is accessible to the Chinese-speaking community worldwide. CIIX provides information on how to purchase bitcoin, real-time market commentary and consulting services, as well as advertising and public relations services.

Cryptocurrency is appealing in that it allows investors to diversify their portfolios. This shift away from traditional investment opportunities brings with it an air of excitement. Bitcoin is being exchanged by investors in unregulated offline platforms in an effort to bypass China’s ban (http://cnw.fm/D3Hxq). The scarcity of bitcoin, and the complexity of mining new coins, is part of the draw. Despite a recent post by China’s Communist Party paper bashing bitcoin and insisting that cryptocurrency is a load of hype, demand has continued to rise (http://cnw.fm/jA6Le).

CIIX is committed to raising awareness and education surrounding bitcoin. The company now hosts a daily broadcast from the NYSE, titled ‘Bitcoin MultiMillionaire’, with the intent of educating Chinese-speaking viewers on the most current news in cryptocurrency. In addition, CIIX is committed to bitcoin growth and has installed a bitcoin ATM in the lobby of its headquarters in San Gabriel, California. The Chinese middle and upper class is growing and looking for new ways to diversify their portfolios. ChineseInvestors.com is ready and able to offer them innovative accessibility to cryptocurrency.

For more information, visit the company’s website at www.ChineseInvestors.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Skinvisible, Inc. (SKVI), Quoin Pharmaceuticals Proposed Merger to Address Opioid Pain Management Market

  • A merger between Skinvisible and Quoin will enable a successful entry on the post-surgical pain management market
  • Opioids – which typically refer to oxycodone, hydrocodone, and fentanyl – are highly addictive painkillers; nearly three in 10 Americans prescribed opioids for chronic pain will abuse them
  • Opioids are becoming increasingly deadly to Americans; in 2016, two-thirds of drug-related deaths involved opioids; in fact, since 1999, opioid-related deaths in the United States have increased nearly fourfold
  • Drug abuse is a burden shared by every state; nearly 63,600 Americans lost their lives to drug overdoses in 2016 – a 21 percent increase over the previous year; from 2000 to 2016, the U.S. Centers for Disease Control and Prevention estimates that more than 600,000 people died from drug overdoses in the United States
  • Every 25 minutes, a baby in the United States is born suffering from opioid withdrawal

Skinvisible, Inc. (OTCQB: SKVI) previously announced the signing  of a Letter of Intent for a proposed merger with Quoin Pharmaceuticals Limited – a partnership that could address significant unmet medical needs on the pain management market. If both parties agree on the terms, the merger should be completed this year, and the resulting entity will operate under the name Quoin Pharmaceuticals Inc. and will continue to trade on the OTCQB market.

Quoin’s strength is within the area of pharmaceutical product development for products that address some of the most serious present-day health problems. Skinvisible is the developer of innovative delivery system technologies that can enhance product delivery and performance.

Quoin’s lead product is QRX001 – a transdermal NMDA receptor antagonist for the effective treatment of pain following surgery.  QRX001 delivers up to 72 hours of effective pain relief after surgical interventions.  Almost 30 clinical studies have been performed to date on the NMDA receptor antagonist, clearly showing that sub-anesthetic doses reduced 24-hour PCA morphine consumption; reduced post-operative nausea and vomiting; reduced pain intensity; resulted in adverse events that were mild or absent; and generated better results than any other single product or combination. The aim of the product is to also reduce the use of opioids for pain management following an operation.

Upon the product’s launch, QRX001 is expected to provide surgeons with a new and effective alternative to opioids. Opioid abuse has reached an epidemic level in the U.S., with opioid overdoses causing more than 90 deaths per day (http://cnw.fm/7vtpP). This number has grown exponentially in the past decade, according to the Centers for Disease Control and Prevention, with opioid use remaining widespread despite the risks. Today, approximately 12 million Americans report that they use pain killers in a non-medicinal way.

The opioid market in the U.S. is estimated at $6 billion annually.  With the opioid epidemic now deemed a National Health Emergency, there is a significant push to find new products that reduce or eliminate their use, particularly in a post-surgical setting, which is where 50 percent of people who become addicted first become exposed to these drugs.

In addition to wrecking lives, opioid abuse poses a massive burden on the economy. Adding up money lost from costs related to health care, addiction treatment, reduced work productivity and crime, the Centers for Disease Control and Prevention estimates that the economic burden of the opioid crisis is more than $78.5 billion per year.

Almost half of the victims were first introduced to opioids after undergoing surgery. According to the National Center for Health Statistics, 100 million surgeries take place in the U.S. every year (http://cnw.fm/k4cxW). At least 50 million of these surgical interventions necessitate the use of post-operative pain management pharmaceuticals.

Currently, the pain management market in the U.S. is fueled by a number of sectors. The most prominent ones include post-operative pain relief, arthritis pain, cancer pain, migraine and neuropathic pain. As larger Western populations age and become susceptible to an array of medical conditions, the need for new pain management developments will grow even further. The partnership between Skinvisible and Quoin perfectly positions the two companies to address these growing unmet needs on the pain management market.

The Skinvisible announcement states that new technologies and product synergies between the two companies could potentially provide significant value to shareholders after the merger. Together, Skinvisible and Quoin could maximize their product development opportunities, as noted by Skinvisible President Terry Howlett.  The official news release also included a disclaimer regarding ‘forward looking’ statements.

For more information, visit the company’s website at www.Skinvisible.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Regulation and Oversight of Virtual Currencies by SEC and CFTC Agencies to be Reviewed, Congressional Hearing Set

  • The Committee on Banking, Housing and Urban Affairs sets hearing for February 6 to review oversight role of the SEC and CFTC over virtual currencies, such as bitcoin
  • In an op-ed written jointly by the SEC and CFTC, agency chiefs say they would support policy efforts to revisit framework of their cryptocurrency regulation; both will testify before the committee
  • Agencies say they will seek to maintain integrity and transparency in the volatile cryptocurrency markets; goal is to protect all market participants and investors

Virtual currency oversight by the Securities and Exchange Commission (SEC) and the U.S. Commodity Futures Trading Commission (CFTC) will be reviewed after the heads of both agencies testify on February 6 before a hearing of the Committee on Banking, Housing and Urban Affairs (http://cnw.fm/Aqb3b).

Jay Clayton, chairman of the SEC, and J. Christopher Giancarlo, chairman of the CFTC, will testify at the hearing. What they will say was telegraphed in their recent jointly-authored op-ed (http://cnw.fm/sb3DN). In it, they noted that most check-cashing and money transmission services are state regulated. They argue that most of the internet-based cryptocurrency trading platforms have registered as payment services and, therefore, are not subject to direct regulation today by the two federal agencies.

Their op-ed said, “Many of the internet-based cryptocurrency trading platforms have registered as payment services and are not subject to direct oversight by the SEC or CFTC. We would support policy efforts to revisit these frameworks and ensure they are effective and efficient for the digital era.”

The agencies said they seek market integrity and transparency. In the op-ed, they note that they seek review of their oversight of these markets and would continue to work with law enforcement to enforce this goal. “The CFTC and SEC, along with other federal and state regulators and criminal authorities, will continue to work together to bring transparency and integrity to these markets and, importantly, to deter and prosecute fraud and abuse,” they added.

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is “One to Watch”

  • U.S. hemp retail market estimated at $1.8 billion by 2020 with 22% CAGR
  • Global hemp-based cannabidiol (CBD) segment projected to reach $3 billion by 2021
  • Disruptive potential for industrial hemp products offers substantial rewards

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF), headquartered in British Columbia, Canada, is a publicly traded company founded in 2014. Global Hemp Group is focused on acquiring and developing a strategic portfolio of like-minded companies that believe in the significant potential of the industrial hemp plant. Global Hemp Group’s focused on attracting joint venture partners across all sectors of the industrial hemp industries with the commitment to improve quality of life by researching, developing and distributing sustainable materials, products and services produced from hemp.

The company’s mission is to build a strategic portfolio of hemp-based companies that operate synergistically to consistently deliver a solid ROI to its shareholders. Global Hemp Group has established the concept of Hemp Agro-Industrial Zone (HAIZ) (https://globalhempgroup.com/hempagro/) in order to build cooperative mechanisms across industrial sectors with a focus on different parts of the hemp plant. Under the HAIZ strategy, Global Hemp Group brings together capital, farmers and labor in an effort to build a “soil-to-shelf” portfolio of complimentary companies and joint venture partners in the global hemp industry.

Global Hemp Group has chosen to only work with suppliers of high quality, sustainable raw materials and finished products derived from the hemp plant. Among the leading industries utilizing industrial hemp’s exceptional properties is the automotive sector, building materials market, bio-composites, energy-related markets, super-foods, nutritional supplements, nutraceuticals and the cannabinoid markets. Guided by the principal theme of “global environmental stewardship,” Global Hemp Group focuses on the key concepts of sustainability and social responsibility in all its endeavors.

Global Hemp Group’s joint venture with publicly traded Marijuana Company of America on hemp cultivation trials in 2017, designed to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada, for the first time in 20 years, was a great success. The partners are preparing for the upcoming changes in Canada’s cannabis legislation that will permit cannabinoid extraction from industrial hemp. Farmers have already been recruited to plant a minimum of 125 acres of industrial hemp for the 2018 growing season, with the goal of increasing the acreage under cultivation to 1,000+ acres by year three of the joint project. Global Hemp Group is preparing an application for a processing license to extract cannabidiol (CBD) and other cannabinoids from the upcoming industrial hemp crop. Discussions are also underway with potential processing partners for the extraction of cannabinoids and straw processing for building materials for the upcoming harvest in October 2018, with a longer term plan to establish permanent processing facilities by October 2019.

Global Hemp Group is led by Charles Larsen as its president, CEO and chairman of the board. Larsen’s more than 30 years of experience working in government, public, private and startup companies as an executive manager includes being the founding president of Medical Marijuana, Inc., the first public company in the Cannabis space. Larsen is also a founder and current director of Marijuana Company of America, Inc., and has been actively involved in the cannabis and hemp industry for nearly a decade. Larsen is joined by Curt Huber, who serves as CFO and director. Huber is an independent corporate and financial consultant with more than 25 years of experience in all facets of public companies among many different sectors including mining, oil and gas, and technology.

Also joining the management team as director is Dr. Paul T. Perrault, an agricultural economist trained in cooperative development and in rural development. Perrault’s experience includes years of consulting on rural development projects introducing new crops in several developing countries and strengthening agricultural research organizations, principally in Africa. Jeff Kilpatrick also serves as a director and is currently a program supervisor of Alachua County Department of Court Services in Gainesville, Florida. Kilpatrick, who spent 21 years in the U.S. Coast Guard, is a member of LEAP – Law Enforcement Against Prohibition – and is president elect for the National Association of Pretrial Services Agencies (NAPSA).

Global Hemp Group’s business philosophy is “A healthier future through sustainable business strategies.”

For more information, visit the company’s website at www.GlobalHempGroup.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net